Abstract
Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Keywords: Alzheimer’s disease, differential diagnosis, serum biomarkers, tau fragments.
Current Alzheimer Research
Title:Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Volume: 12 Issue: 9
Author(s): D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm
Affiliation:
Keywords: Alzheimer’s disease, differential diagnosis, serum biomarkers, tau fragments.
Abstract: Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Export Options
About this article
Cite this article as:
Inekci D., Henriksen K., Linemann T., Karsdal M.A., Habib A., Bisgaard C., Eriksen F.B. and Vilholm O.J., Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/1567205012666150710111211
DOI https://dx.doi.org/10.2174/1567205012666150710111211 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gliogenesis and Glial Pathology in Depression
CNS & Neurological Disorders - Drug Targets Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Current Quest in Natural Bioactive Compounds for Alzheimer’s Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence
Current Drug Targets The Anterior-posterior Functional Connectivity Disconnection in the Elderly with Subjective Memory Impairment and Amnestic Mild Cognitive Impairment
Current Alzheimer Research Severe Mental Disorders from a Cognitive-Behavioural Perspective: A Comprehensive Review from Conceptualization to Intervention
Current Psychiatry Reviews Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Treatment and Prevention of Alcohol Hangover
Current Drug Abuse Reviews Is Age of 80 Years a Threshold for Carotid Revascularization?
Current Cardiology Reviews Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Potential Protective Effect of Dl-3-n-butylphthalide on Chronic Cerebral Ischemia Brain Injury
CNS & Neurological Disorders - Drug Targets The Role of Chinese Herbs and Acupuncture on the Inflammation Reaction After Cerebral Ischemia
Current Pharmaceutical Design Medicinal Chemistry of Potassium Channel Modulators: An Update of Recent Progress (2011-2017)
Current Medicinal Chemistry Delirium in Older Patients – A Review
Current Psychiatry Reviews Anti-Alzheimer, Antioxidant Activities and Flavonol Glycosides of Eryngium campestre L.
Current Chemical Biology New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Role of Psychiatrists in the Diagnosis and Management of Alzheimer's Disease “Revisited”: A Review and Clinical Opinion
Current Psychiatry Reviews Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Nanotechnology Based Diagnostic and Therapeutic Strategies for Neuroscience with Special Emphasis on Ischemic Stroke
Current Medicinal Chemistry